VRNA vs. ONC, BNTX, TEVA, SMMT, ITCI, GMAB, RDY, ASND, VTRS, and QGEN
Should you be buying Verona Pharma PLC American Depositary Share stock or one of its competitors? The main competitors of Verona Pharma PLC American Depositary Share include BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.
Verona Pharma PLC American Depositary Share vs. Its Competitors
Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.
In the previous week, Verona Pharma PLC American Depositary Share had 7 more articles in the media than BeOne Medicines. MarketBeat recorded 8 mentions for Verona Pharma PLC American Depositary Share and 1 mentions for BeOne Medicines. Verona Pharma PLC American Depositary Share's average media sentiment score of 1.37 beat BeOne Medicines' score of 0.00 indicating that Verona Pharma PLC American Depositary Share is being referred to more favorably in the media.
Verona Pharma PLC American Depositary Share has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500.
Verona Pharma PLC American Depositary Share presently has a consensus price target of $107.36, indicating a potential upside of 17.75%. BeOne Medicines has a consensus price target of $320.67, indicating a potential upside of 30.62%. Given BeOne Medicines' higher possible upside, analysts clearly believe BeOne Medicines is more favorable than Verona Pharma PLC American Depositary Share.
Verona Pharma PLC American Depositary Share has higher earnings, but lower revenue than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than Verona Pharma PLC American Depositary Share, indicating that it is currently the more affordable of the two stocks.
Verona Pharma PLC American Depositary Share has a net margin of 0.00% compared to BeOne Medicines' net margin of -9.40%. BeOne Medicines' return on equity of -7.55% beat Verona Pharma PLC American Depositary Share's return on equity.
85.9% of Verona Pharma PLC American Depositary Share shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 4.8% of Verona Pharma PLC American Depositary Share shares are owned by company insiders. Comparatively, 6.6% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Verona Pharma PLC American Depositary Share beats BeOne Medicines on 9 of the 15 factors compared between the two stocks.
Get Verona Pharma PLC American Depositary Share News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verona Pharma PLC American Depositary Share Competitors List
Related Companies and Tools
This page (NASDAQ:VRNA) was last updated on 7/7/2025 by MarketBeat.com Staff
